Drug & intervention
telisotuzumab vedotin
RxCUI 2721996
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Clinical trials
4 shownA Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT06568939 · 2025-01-20
RECRUITINGStudy of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met ProteinNCT06093503 · 2024-05-31
WITHDRAWNStudy of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung CancerNCT03539536 · 2018-10-10
ACTIVE_NOT_RECRUITINGExpanded Access to Telisotuzumab VedotinNCT04830202
TEMPORARILY_NOT_AVAILABLEConditions being studied
Research locations
BeijingBeijing Municipality, China2ChicagoIllinois, United States2FairfaxVirginia, United States2FuzhouFujian, China2HaifaIsrael2HarbinHeilongjiang, China2HonoluluHawaii, United States2JacksonvilleFlorida, United States2Los AngelesCalifornia, United States2NagoyaAichi-ken, Japan2NashvilleTennessee, United States2WuhanHubei, China2
Leading sponsors
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.